Nick Paul Taylor

Moderna has suffered its second PMCPA rebuke in quick succession. Days after ruling Moderna had brought discredit on the industry, the U.K. self-regulatory body reached the same damning conclusion in a separate case.

Phreesia has generated evidence that exposing patients to vaccine messages at the point of care boosts the vaccination rate, including among historically marginalized groups.

Shattuck Labs has hammered another nail into the coffin of CD47. After seeing a “modest” effect on survival in blood cancer, the biotech axed its

Gritstone bio has brought in bankers to explore “potential value-maximizing strategies” after its phase 2 colorectal cancer vaccine data fell short of the runaway success needed to transform its fortunes.

Hologic is asking women to #BustTheMyth this Breast Cancer Awareness Month. The provider of breast health products has put a set of myths about

Zephyrm Bioscience is gusting toward the Hong Kong stock exchange, filing (PDF) for an IPO to bankroll phase 3 trials of its cell therapy in a lung condition and graft-versus-host disease (GvHD).

Lundbeck has tapped Charles River Laboratories' artificial intelligence capabilities to aid the discovery of neuroscience treatments, partnering with the service provider to use Logica in its research projects.

Septerna is about to find out how a biotech without “any meaningful clinical data” fares in the late 2024 IPO market.

Real Chemistry has partnered with Corv

Pi-Cardia designed the Shortcut device to mitigate the risk of coronary artery obstruction by splitting aortic valve leaflets before valve placement.